Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.biocon.com | |
Market Cap | 31,707.85 Cr. | |
Enterprise Value(EV) | 47,542.75 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 10.00 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 26.42 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 164.58 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.60 | Calculated using Price: 264.10 |
Dividend Yield | 0.57 | Period Ending 2023-03 |
No. of Shares Subscribed | 120.06 Cr. | 1,200,600,000 Shares |
FaceValue | 5 | |
About Biocon Ltd. | ||
The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. |
1 Day |
|
+2.94% |
1 Week |
|
+7.01% |
1 Month |
|
-4.19% |
3 Month |
|
+4.51% |
6 Month |
|
-0.19% |
1 Year |
|
+27.82% |
2 Year |
|
-24.29% |
5 Year |
|
-12.29% |
10 Year |
|
+282.05% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 17.22 | 16.91 | 15.74 | 9.17 | 18.01 | 14.26 | 12.03 | 9.83 | 4.98 | |
Return on Capital Employed (%) | 15.3 | 14.33 | 12.83 | 9.21 | 16.12 | 14.35 | 10.56 | 8.3 | 5.37 | |
Return on Assets (%) | 8.72 | 8.25 | 7.83 | 4.77 | 9.26 | 6.94 | 5.24 | 4.03 | 1.79 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 3,271 | 4,034 | 4,838 | 5,181 | 6,098 | 6,706 | 7,627 | 8,433 | 17,867 | 18,982 | |
Non Curr. Liab. | 1,378 | 2,421 | 2,305 | 2,007 | 2,122 | 2,685 | 5,497 | 6,803 | 20,742 | 19,554 | |
Curr. Liab. | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,170 | 3,828 | 8,511 | 10,366 | |
Minority Int. | 172 | 266 | 376 | 468 | 609 | 677 | 881 | 1,038 | 4,622 | 5,295 | |
Equity & Liab. | 6,375 | 8,387 | 9,197 | 9,796 | 11,868 | 14,076 | 18,215 | 20,101 | 51,742 | 54,198 | |
Non Curr. Assets | 3,813 | 4,416 | 5,149 | 5,648 | 6,979 | 8,751 | 10,614 | 11,718 | 39,408 | 40,128 | |
Curr. Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,548 | 8,382 | 12,334 | 14,070 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 6,375 | 8,387 | 9,197 | 9,796 | 11,868 | 14,076 | 18,215 | 20,101 | 51,742 | 54,198 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,301 | 7,143 | 8,184 | 11,174 | 14,613 | |
Other Income | 53 | 84 | 157 | 206 | 414 | 508 | 605 | 690 | 768 | 972 | |
Total Income | 3,143 | 3,431 | 4,048 | 4,330 | 5,929 | 6,808 | 7,748 | 8,874 | 11,942 | 15,584 | |
Total Expenditure | -2,394 | -2,584 | -2,912 | -3,294 | -4,391 | -5,044 | -5,841 | -6,691 | -9,055 | -11,232 | |
PBIDT | 749 | 847 | 1,137 | 1,035 | 1,538 | 1,765 | 1,907 | 2,183 | 2,888 | 4,352 | |
Interest | -9 | -29 | -26 | -62 | -71 | -65 | -58 | -68 | -419 | -996 | |
Depreciation | -221 | -249 | -277 | -385 | -448 | -552 | -715 | -814 | -1,113 | -1,526 | |
Taxation | -96 | -142 | -162 | -157 | -212 | -315 | -222 | -212 | -254 | -213 | |
Exceptional Items | 105 | 161 | 195 | 68 | 13 | -111 | -291 | -6 | |||
PAT | 528 | 609 | 688 | 453 | 1,003 | 900 | 846 | 772 | 643 | 1,611 | |
Minority Interest | -31 | -59 | -76 | -81 | -97 | -123 | -106 | -123 | -180 | -289 | |
Share Associate | -122 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 497 | 550 | 612 | 372 | 905 | 748 | 741 | 648 | 463 | 1,200 | |
Adjusted EPS | 4 | 5 | 5 | 3 | 8 | 6 | 6 | 5 | 4 | 10 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 561 | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | |
Cash Fr. Inv. | -938 | -509 | -1,142 | -499 | -684 | -714 | -1,559 | -3,625 | -1,699 | -14,282 | |
Cash Fr. Finan. | 426 | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | |
Net Change | 49 | -112 | 297 | -36 | -262 | 199 | 112 | 99 | -280 | 619 | |
Cash & Cash Eqvt | 557 | 463 | 758 | 710 | 449 | 659 | 825 | 897 | 654 | 1,295 |
Thu, 28 Mar 2024
Trading Window Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Thu, 28 Mar 2024
Trading Window-XBRL Biocon Limited has informed the Exchange about Closure of Trading Window |
Wed, 27 Mar 2024
Press Release Biocon Limited has informed the Exchange regarding a press release dated March 27, 2024, titled "Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.". |
Thu, 28 Mar 2024 |
Closing Above Previous High |
Making Higher Highs for 3 days |
Close Within 52 Week High Zone |
Close Entering 52 Week High Zone |
Close Above Last Week High |